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Case reports and case series remain an important part of journals and are often first to 
document medical breakthroughs. This article reviews their characteristics, aims and 
limitations. It provides information on how to increase the validity of the bedside 
decision-making process that these studies report, using tools such as validated 
outcomes and split body or n-of-1 trials. A section describing tools to improve writing 
of case reports and case series provides suggestions for detailed reporting and good 
evaluation of novelty, validity and relevance. It includes general and British Journal of 




Case reports and case series are an important feature of many journals. A recent 
analysis of the British Journal of Dermatology (BJD) manuscripts showed that they 
represented 9% of the BJD papers in 2015.1 Case reports are an immediate reflection 
of clinical practice and remain attractive to readers. They invite thought and 
speculation, remind readers of forgotten conditions and are relatively easy to write 
and read, but their important role in medicine can be overlooked compared to other 
study designs within the evidence pyramid.  Case series are a step forward in terms of 
elaboration, especially if prospective, but they share many characteristics of case 
reports and most of the content of this paper equally applies to them. While these 
papers naturally have methodologically weaknesses2, they have often been first to 
document medical breakthroughs.3 Some examples are the initial description of AIDS 
and toxic epidermal necrolysis, new therapies such as cyclosporine for psoriasis and 
propranolol for haemangiomas and rare or delayed adverse effects of interventions 
such as the risk of multifocal leukoencephalopathy with efalizumab.4 
 
From the journals perspective, case reports, however popular with readers, generally 
reduce the journals’ impact factor.1,5 This has led to many journals abandoning them 
altogether or at least to restrict the selection of cases to those with the highest impact 
on readers and the research field. 
 
Case reports and series can serve different purposes in dermatology (Table 1). 
Sometimes they do not include new information, but act as an introduction to put a 
review into perspective or as a learning aid, increasing our proficiency as visually 
literate clinicians.6 Cases can describe new unusual findings for common conditions or 
improve our knowledge about uncommon diseases. Exceptional reports lead to a new 
hypothesis and can be the starting point of further research. 
 
Guidance for writing good reports is limited. Jenicek’s textbook on case reporting in 
evidence-based medicine7 is one of the few extensive texts on this topic. Important 
missing information is one of the frequent deficiencies2  that can be improved  
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following available case report (CARE) reporting standards.8,9 We believe that other 
aspects of writing a good case report can be learned and planned.  
 
The objective of this paper is to help authors of case reports and case series to 
improve their manuscripts and their chances of getting them published.  We provide 
background information on the definition and limitations of case reports and series, 
and then discuss tools to improve them, including some BJD-specific suggestions. 
 
Definition and limitations of case reports and case series 
 
Case reports, case series and cohort studies.  Where are the boundaries? 
 
Case reports and case series share many characteristics and limitations. Case 
series refer to any report of more than one case. Some of them are a 
retrospective description of noteworthy cases, while others are planned and 
prospective.  
 
For papers that describe the association between an exposure and an outcome, it 
might be difficult to make a clear distinction between a case series and a cohort 
study.  The main difference is that cohort studies define the sampling method and 
the population from which the cases are selected.10 This permits the calculation of 
absolute risks. Case series cannot do this, because the source population and 
the sampling method are unclear. If you can clearly define the sampling 
method of your case series, you should aim to produce a small cohort study 
and guidance for cohorts might be more useful for you. 
 
Not all case series report a follow-up, and many might also be cross-sectional studies 
with a poorly defined sampling method.  Sometimes case series are wrongly labelled as 
case-control studies, if they have a control group. The main difference is that, in case-
control studies, patients are sampled based on the presence of an outcome, and time 
is a subtle but integral part of the design: the aim being to measure the differences in 
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an exposure that takes place earlier. Again, a defined sampling method makes the 
difference.  
Why do case reports and case series provide poor evidence?  
 
Findings in case reports and case series are prone to the deleterious effects of 
chance and bias, particularly selection bias, information bias and publication bias.  
 
The effect of chance is more noticeable when the number of patients is low. If we 
have a single case, findings can be the norm in the reference population or an 
oddity. With small case series we will not have power to detect differences in the 
risk of an outcome, especially if it is uncommon. Therefore, failure to observe an 
adverse effect in a small series is to be expected. Small series cannot define overall 
safety, but they may indicate a signal.  The same is true for therapy. With low 
numbers of patients, apparent treatment success may be due to chance.  
 
Selection bias affects any report from a larger population that may be cherry picked: 
is the population in the paper representative of the source population?  An 
extraordinary outcome may be representative of a group or an aberration; and 
thus, the sampling method must be clear. Extraordinary patients at baseline are 
more likely to show normal results in larger follow-up studies, and this is referred to 
as regression to the mean. 
 
Information bias refers to an error due to inadequate assessment of the results of a 
case report, frequently showing unjustified optimism. This bias is more likely when 
relying on fuzzy assessments of improvement or non-standardized patient-reported 
outcomes, rather than more reproducible outcomes, like complete resolution of 
disease, death, or validated scales. 
 
Publication bias describes the common observation that positive findings overwhelm 
the rarely published negative reports.7  Negative reports (lack of benefit or harm) 
teach us caution and balance the optimism inherent to positive reports, helping to 
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avoid unnecessary treatment attempts and their adverse effects.  Negative therapeutic 
case reports rarely tell the whole story because no treatment works in everyone; 
hence we need follow-up case series. Publication bias is an important limitation of 
systematic reviews that include case series. 
 
Given the low validity of case reports to detect associations, better designed studies 
are usually required to confirm their findings. What kind of study depends on the aim 
of the report. Unfortunately, this rarely happens, and there are often no further 
studies. Even in high-impact general medical journals such as the Lancet, case reports 
and series of new interventions lead to randomized controlled trials (RCTs) in about 
25% of cases.11 Despite this lack of additional more valid data, second, third and fourth 
line therapy in rare diseases is frequently informed by weak evidence from case 
reports or series, when better evidence is lacking.  
 
How to improve your case report or case series? 
 
Having described the inherent weaknesses in case reports and case series, how can we 
improve their quality? It helps to know in advance what to do to increase the validity 
of the report. At the time of writing up the case, your report can only be partially 
enhanced.  
 
Before writing: improving case reports at the bedside 
 
Just as you see the patient and think about writing a case report, a few simple 
measures can be very helpful. The best way to reduce the effect of chance is to 
increase the number of participants:  can you include more patients and transform 
your case report into a case series (ideally prospective and consecutive) or a cohort 
study?  
Reporting consecutive patients in a case series, instead of a selection of them, is 
important to reduce selection bias. This usually means a prospective study, but could 
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also be achieved using patients’ records. You should also think of using a validated 
outcome measure instrument to describe the outcome that you are reporting.  
 
There are more sophisticated tools to improve the validity of your report. For topical 
therapies without systemic effect, a split body study comparison (i.e. using a therapy 
on one side and no therapy on the other) increases the validity of the results. This can 
be randomized and blinded to the observer. 
The timing of events is a standard argument for causation, and the effect of 
withdrawal of therapy and re-challenge can strongly support your message. A more 
sophisticated application of this approach is the single patient (n-of-1) trial. This 
method is useful if you are describing a disease that is chronic and stable and a fast 
and short-acting therapy with an easy to measure outcome and doubtful results. The 
approach involves successive periods of treatment with the drug or a placebo, in 
agreement with the patient and with proper consent, to find out if the therapy works 
or not. Periods of therapy should be randomized and blinded and results should be 
measured objectively. A dermatological example has shown that tetracycline 
decreases the number of new bullae in a patient with epidermolysis bullosa simplex.12 
Similarly to confirming effective treatment, n-of-1 trials can also confirm causality of 
adverse events, when symptoms disappear on exposure to placebo. There is good 
guidance on how to perform n-of-1 trials12-15 , which do not require special 
authorization if they are used as a decision-making tool for an individual patient. If 
they go beyond compassionate use, and the trial is primarily used to evaluate a new 
therapy, it becomes a phase I/II study.16  If in doubt, the local clinical ethics committee 
can advise. The main hurdle will be having a pharmacist to prepare the blinded drug 
and placebo.  You might also need some help to analyse the results. Results of 
published n-of-1 trials can be merged using meta-analysis and this can help in the 
description of therapies for rare diseases.17  
 
Writing your report: everything that is needed but not more 
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Aim for the right target: What is the message of your report? 
 
The first step when you begin to write your case report is to have a clear message: 
what makes your case outstanding and justifies its publication? This will organize your 
report in a logical form and help select the appropriate journal.  How would you 
classify your report into the groups described in table 1?  
 
Having a clear message should lead to a well-defined line of reasoning in your paper. 
As in other types of scientific manuscripts, the contents should organize around this 
main idea:  write a short introduction that points to this key question as an unsolved 
problem, answer it with your case, discuss its credibility and value in the discussion 
and give a final sentence with your main message in the conclusion. Focus on this and 
avoid loading up your paper with more, secondary, topics. 
 
Not all journals will publish all types of case reports. Some do not have a clear policy, 
some want only original findings, others are willing to publish reports of very 
uncommon findings, and some prefer to publish reports that focus on education.  
 
Under the current authors guidance, the closest the BJD has to an educational case 
report is a critically appraised topic (CAT). This is a formalized literature review that is 
framed by a clinical case, and its methods have been recently described.18  
For reports that describe unusual findings or simple messages, the BJD has the Image 
Gallery section where the visually arresting and thought-provoking cases can be 
published. Lastly, if your report generates a new hypothesis, this is our preferred type 
of manuscript for the case reports section. Due to their improved validity, n-of-1 trials 
are a welcome methodology for reports in the BJD. Examples in table 1 can also help 
you decide on the best BJD section for your paper. 
 
Having a clear message and submitting your paper to the right section of the journal is 
the first step to improve your chances of publication. The second step is writing a clear 
and detailed manuscript. 
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Help users of the case report: give all the information, using available tools 
 
Who might use your case report? Clinicians might look for the information that you 
report to apply it to their patient and researchers might consider adding your paper to 
a review, or testing your hypothesis in a study. Give enough details to ensure that both 
types of readers will find the information that they need. Many reports suffer from 
lack of detail, such as incomplete description of the intervention or follow-up, where it 
could easily be supplied.2 Reviewers will check that your case report is detailed, new, 
valid, and relevant. 
Description of the case: ensure detailed reporting 
 
When describing the case or case series, use existing tools to ensure complete 
reporting. Many reporting guidelines are available through the EQUATOR network.19 
CARE guidelines are specific for case reports and include a useful template.8 They 
cover the basic structure of case reports and are helpful for authors, but assume full 
length papers in conflict with space limitations of journals. As a consequence, many 
dermatology journals cannot fully comply with CARE guidelines.20  There are general 
guidelines for complete description of interventions 21 and extensions on specific 
interventions of guidelines for randomized controlled clinical trials. An easy check to 
assure replicability is to show your report to a colleague and ask if they could replicate 
the intervention. If you are reporting an adverse effect, certain details are vital and 
authors should follow specific reporting guidelines22 to optimize the discussion of 
alternative causes, drug details, or drug interaction. Describing if you have reported 
your case to the pharmacovigilance system is important to avoid double counting of 
events. 
The discussion: is it new? 
 
The discussion section of a case report is the place to highlight the contribution of your 
paper to the literature. From personal experience, the causes for the last 177 
immediate rejections of case reports in the BJD were lack of novelty (23%), lack of 
validity (16%) and unclear relevance (8%), or a combination of these reasons (52%). Try 
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your best not to fall into these categories, but do not exaggerate. Unfounded claims 
are easily recognised, and annoy reviewers, editors and readers. 
Are you reporting something new? Describe your findings in the context of previous 
knowledge. You should be exhaustive in the appraisal of the literature on the topic 
before submitting.  We suggest that you use validated literature search filters to search 
for previous reports. The InterTASC Information Specialists' Sub-Group Search Filter 
Resource is an excellent, regularly updated resource.23 Adding a reference for the 
search filter you used, or adding your search strategy as a supplementary material 
could help readers judge if your search was comprehensive. Claims of ‘firstness or 
uniqueness’ are usually unnecessary hyperbole and subject to challenge. “We have no 
found previous descriptions of XX” is better than claiming that yours is the first 
description. If there are previous reports, describe what your report adds to previous 
ones and concisely compare it with them.  
 
The discussion: comment on validity and relevance 
 
Validity needs to be addressed.  Criteria are more stringent for case series that should 
discuss the effect of chance using confidence intervals, and attempt to define an 
underlying population and describe selection bias.   
 
What is the effect of chance in your results? If you report several cases, whether on 
your own or as a review of published cases, use 95% confidence intervals to highlight 
the effect of chance. A new therapy that improves 6 of 8 patients (75%) may seem 
impressive, but a 95% confidence that ranges from 35 to 99% improvement rate curbs 
over-enthusiasm. The rule of three is a simple estimation24,25 that can be used for 
series with zero events. Absence of adverse events is frequently seen when discussing 
safety in a case series.  As an example, 20 patients with previous hepatitis B infection 
were treated with biologics, and none showed a reactivation of infection.26 While 
common sense suggests that 20 is a small number, the rule of three indicates that the 
upper 95% confidence interval in the sample is 3 cases out of 20 (3/n), or 15%. The 
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correct interpretation of that paper is that the findings are compatible with up to a 
15% reactivation of infection, and this should be highlighted in the discussion.  
 
Any confidence interval is only as useful as the data it describes. Authors should 
provide information to help understand the magnitude of selection bias:  did cases 
come from a single institution or from several departments? Were they collected in a 
primary care or specialized setting?  How were patients identified? Were they 
collected from memory or by searching specific databases? Which patients may have 
been missed? Did you report all those that responded to therapy or those that 
received it?  As a rule, all consecutive patients should be reported.  
 
Further discussion about validity can make use of timing of events and the expected 
outcomes. Description of an association between improvement and the intervention is 
not a proof of causation, and you need to convince the readers of the validity of your 
observation. A timeline that clarifies the temporal correlation is frequently helpful, the 
CARE guidelines give some guidance on how to write these timelines.27 Knowing the 
natural course of the disease or the usual response on standard treatment is key 
information. All or nothing effects provide more compelling evidence.28  
 
Usually a lengthy part of the discussion that can free up space for needed clinical 
details are the speculations about a mechanism of action.2 
 
Discussion of analogous situations can also be helpful. Similar outcomes to similar 
exposures can be discussed, ideally based on clinical results. Any marketed therapy has 
plenty of clinical data available that can be referenced and might be useful in new 
indications. 
 
When the value of the data has been established, you need to explain the relevance of 
your report. What are the practical consequences of your paper? What is the 
hypothesis that can be derived from your report and what is the next step to evaluate 
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Case reports and case series are here to stay. They provide immediate exposure to 
new developments and stimulate original ideas, but are prone to bias and over-
generalisation. Their role and relevance should not be undervalued, but all efforts 
should be made to improve their standards by using existing tools.   
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Table 1. The purpose of dermatological case reports and case series with examples 
 
Purpose Comments BJD example 
Case reports that do not provide new information (“reminders”) 
To teach using cases No new information.  
1. They may simply remind 
of a finding/diagnosis 
2. The key message is the 
review. CAT (Critically 
appraised topic) is a form 
that merges a case report 
framing a clinical question 
with a formalized review 
1.  Image Gallery: Nail 
involvement in syphilis: the 
great forgotten29 
2. Is Mohs micrographic 
surgery more effective 
than wide local excision for 
treatment of 
dermatofibrosarcoma 
protuberans in reducing 
risk of local recurrence? A 
Critically Appraised Topic30 
Case reports that provide some new clinical information 
To increase our clinical 
knowledge about known 
diseases 
Three main types:  
1. Describing unusual 
presentations of common 
disorders: “the tails of the 
normal curve”  
2. Improving description of 
uncommon disorders or 
findings, usually through a 
case series 
3. Description of 
associations (some may be 
due to chance) 
1. Massive localized 
lymphoedema31 
2. Skin manifestations 
among GATA2-deficient 
patients32.(case series) 
3. Pyoderma gangrenosum 
associated with 
azacytidine33 
Case reports that lead to new hypothesis 
To describe new 
dermatological conditions 
A novel disease or clinical 
finding, including results of 
A foot tumour as a new 
form of late Lyme 
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or findings tests disease34 
 
To describe new 
dermatological therapies 
 Granulocyte and monocyte 
apheresis for juvenile 
generalized pustular 
psoriasis with mutation of 
the IL36RN gene35 
To describe new adverse 
effects of therapies 
Rare adverse effects might 
not appear in randomized 
clinical trials or cohorts, 
and might only be 
described in case reports 
Teriparatide used for 
osteoporosis and leading 
to worsening of 
calcinosis36 (case series) 
To provide insights into the 
mechanisms of disease 
Some reports describe 
findings that could provide 
new hypothesis for 
pathophysiological 
research 
Small-fibre neuropathy as 
a possible explanation of 
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